Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth ReFacto promotion cited by FDA

Executive Summary

Wyeth discontinues ReFacto promotional brochure after FDA cites unsubstantiated safety claims. ReFacto material claimed "albumin-free final formulation for unsurpassed viral safety," FDA's Feb. 2 1letter says. "FDA is unaware of any data supporting the claim." Low ReFacto demand is causing Wyeth to close St. Louis manufacturing facility (2"The Pink Sheet" Jan. 26, 2004, p. 36)...

You may also be interested in...



Wyeth Closes ReFacto And Premarin Facilities, Cites Low Demand As Reason

Wyeth is closing its ReFacto manufacturing plant in St. Louis due to lower demand for the antihemophilic Factor VIII product

QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

UsernamePublicRestriction

Register

PS043323

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel